News

RedHill Biopharma Reports 2014 Fourth Quarter and Year-End Financial Results

RedHill Biopharma Reports 2014 Fourth Quarter and Year-End Financial Results   RedHill Biopharma Reports 2014 Fourth Quarter and Year-End Financial Results – Hebrew

Read More...

RedHill Biopharma to Host 2014 Fourth Quarter and Year-End Financial Results Conference Call on February 26 2015

RedHill Biopharma to Host 2014 Fourth Quarter and Year-End Financial Results Conference Call on February 26 2015

Read More...

RedHill Biopharma Announces Full Exercise of Underwriters’ Over-Allotment Option

RedHill Biopharma Announces Full Exercise of Underwriters’ Over-Allotment Option   RedHill Biopharma Announces Full Exercise of Underwriters Over-Allotment Option – Hebrew

Read More...

RedHill Biopharma Announces Closing of Public Offering of its American Depository Shares

RedHill Biopharma Announces Closing of Public Offering of its American Depository Shares   RedHill Biopharma Announces Closing of Public Offering of its American Depository Shares – Hebrew

Read More...

RedHill Biopharma to Present at the Life Sciences Israel™ 2015 3rd Annual International Partnering Conference

RedHill Biopharma to Present at the Life Sciences Israel™ 2015 3rd Annual International Partnering Conference

Read More...

RedHill Biopharma Prices Public Offering of its American Depository Shares

RedHill Biopharma Prices Public Offering of its American Depository Shares   RedHill Biopharma Prices Public Offering of its American Depository Shares – Hebrew

Read More...

RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares

RedHill Biopharma Announces Proposed Public Offering of its American Depository Shares   RedHill Biopharma Announces Proposed Public Offering of American Depository Shares – Hebrew

Read More...

RedHill Biopharma Provides Update on Progress with RHB-104 Ongoing Phase III Program for Crohn’s Disease Following FDA Meeting

RedHill Biopharma Provides Update on Progress with RHB-104 Ongoing Phase III Program for Crohn’s Disease Following FDA Meeting   RedHill Biopharma Provides Update on Progress with RHB-104 Ongoing Phase III Program for Crohn’s Disease Following FDA Meeting – Hebrew

Read More...

RedHill Biopharma to Present at the 17th Annual BIO CEO & Investor Conference

RedHill Biopharma to Present at the 17th Annual BIO CEO & Investor Conference

Read More...

Dr. Saleh Naser of The University of Central Florida discusses RedHill’s RHB-104 Phase III Crohn’s study on WNDU

http://www.wndu.com/home/headlines/Closing-in-on-a-cure-for-Cr-289967771.html  

Read More...

News